Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Incretin-based therapies: focus on effects beyond glycemic control alone.

Davidson JA.

Diabetes Ther. 2013 Dec;4(2):221-38. doi: 10.1007/s13300-013-0040-0. Epub 2013 Sep 21.

2.

Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.

Campbell RK.

Clin Ther. 2011 May;33(5):511-27. doi: 10.1016/j.clinthera.2011.04.015. Review.

PMID:
21665040
3.

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.

Cornell S.

J Clin Pharm Ther. 2012 Oct;37(5):510-24. doi: 10.1111/j.1365-2710.2012.01342.x. Epub 2012 Mar 21. Review.

PMID:
22436069
4.

CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?

Mora PF, Johnson EL.

Endocr Pract. 2017 Jan;23(1):89-99. doi: 10.4158/EP161481.RA. Epub 2016 Nov 7.

PMID:
27819769
5.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Deacon CF, Mannucci E, Ahrén B.

Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Review.

PMID:
22471248
6.

Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists.

Gallwitz B.

Rev Diabet Stud. 2009 Winter;6(4):247-59. doi: 10.1900/RDS.2009.6.247. Epub 2009 Dec 30.

7.

Efficacy and safety of incretin based therapies: clinical trial data.

White J.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S30-40. doi: 10.1331/JAPhA.2009.09079. Review.

PMID:
19801363
8.
9.

Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.

Boland CL, Degeeter M, Nuzum DS, Tzefos M.

Ann Pharmacother. 2013 Apr;47(4):490-505. doi: 10.1345/aph.1R444. Epub 2013 Apr 2. Review.

PMID:
23548652
10.

Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice.

Umpierrez GE, Meneghini L.

Endocr Pract. 2013 Jul-Aug;19(4):718-28. doi: 10.4158/EP12292.RA. Review.

PMID:
23512382
11.

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review.

Aroda VR, Henry RR, Han J, Huang W, DeYoung MB, Darsow T, Hoogwerf BJ.

Clin Ther. 2012 Jun;34(6):1247-1258.e22. doi: 10.1016/j.clinthera.2012.04.013. Epub 2012 May 18. Review. Erratum in: Clin Ther. 2014 Feb 1;36(2):307-8.

12.

Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.

Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, Li M, Zhang S, Jia J, Shao S, Xie J, Yang Y, Yu X.

Cardiovasc Diabetol. 2017 Mar 1;16(1):31. doi: 10.1186/s12933-017-0512-z.

13.

Cardiovascular biology of the incretin system.

Ussher JR, Drucker DJ.

Endocr Rev. 2012 Apr;33(2):187-215. doi: 10.1210/er.2011-1052. Epub 2012 Feb 8. Review.

14.

Incretin-based therapies.

Neumiller JJ.

Med Clin North Am. 2015 Jan;99(1):107-29. doi: 10.1016/j.mcna.2014.08.013. Epub 2014 Oct 18. Review.

PMID:
25456646
15.

Blood pressure-lowering effects of incretin-based diabetes therapies.

Lovshin JA, Zinman B.

Can J Diabetes. 2014 Oct;38(5):364-71. doi: 10.1016/j.jcjd.2014.05.001. Review.

PMID:
25284699
16.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796
17.

Differentiating incretin-based therapies for population-based health care.

Calabrese D.

Am J Manag Care. 2011 Mar;17(2 Suppl):S52-8.

18.

Use of incretin-based therapy in hospitalized patients with hyperglycemia.

Umpierrez GE, Schwartz S.

Endocr Pract. 2014 Sep;20(9):933-44. doi: 10.4158/EP13471.RA.

PMID:
25100362
19.

Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.

Neumiller JJ.

Clin Ther. 2011 May;33(5):528-76. doi: 10.1016/j.clinthera.2011.04.024. Review.

PMID:
21665041
20.

Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

Neumiller JJ.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S16-29. doi: 10.1331/JAPhA.2009.09078. Review.

PMID:
19801361

Supplemental Content

Support Center